Intraperitoneal Therapy for Ovarian Cancer (PDF)

Name: Intraperitoneal Therapy for Ovarian Cancer
Brand: Springer-Verlag GmbH
SKU: 30038385
Price: 96.29 EUR
Availability: OnlineOnly

(Sprache: Englisch)

Autor: Mary Clouser

Schreiben Sie einen Kommentar zu "Intraperitoneal Therapy for Ovarian Cancer".

Intraperitoneal Therapy for Ovarian Cancer, Mary Clouser

Merken

Mehr zum Inhalt Autorenporträt Video

eBook (pdf) 96.29 €

Buch (Gebunden) 106.99 €

sofort als Download lieferbar

Bestellnummer: 30038385

Printausgabe 106.99 €

eBook (pdf) -10% 96.29 €

Download bestellen

Verschenken

48 DeutschlandCard Punkte sammeln

Lastschrift, Kreditkarte, Paypal, Rechnung
Kostenloser tolino webreader

Produktdetails

Produktbeschreibung
Autorenporträt
eBook Hilfe
Biblio. Angaben / Produktdetails

Produktinformationen zu „Intraperitoneal Therapy for Ovarian Cancer (PDF)“

Intraperitoneal chemotherapy is increasingly being used as first-line treatment for ovarian cancer. Nevertheless, it is difficult for the oncologist to find a definitive text that documents both the fundamental methods required to optimize therapy and the up-to-date results of phase I, II, and III clinical trials. With this in mind, the editors of Intraperitoneal Therapy for Ovarian Cancer have assembled a team of highly experienced clinicians and researchers to cover every aspect of the subject. The topics addressed include treatment principles, patient, drug, and catheter selection, administration guidelines, the role of hyperthermia, supportive care requirements, novel drugs, and the most recent results of clinical trials. This book will be an invaluable source of information for both practicing clinical oncologists and oncologists in training, oncologists and basic and translational scientists in training.

Autoren-Porträt von Mary Clouser

Prof. Alberts is Director of the Arizona Cancer Center in Tucson, AZ.
He led a workshop on intraperitoneal chemotherapy in January 2006 at the Gynecologic Oncology Group meeting with 400 oncologists and nurses present. He also published the results of the first ever phase III trial comparing IV to IP chemotherapy in the New England Journal of Medicine.